2025年3月16日 · Evolocumab (brand name Repatha) is a PCSK9 inhibitor used for hypercholesterolemia (high cholesterol) and cardiovascular risk reduction. It is given by injection under the skin (subcutaneously) 1 time a month or every 2 weeks.

Evolocumab, [6] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).

2025年3月12日 · Repatha (evolocumab) is a PCSK9 inhibitor used to lower high cholesterol alongside dietary changes and to reduce the risk of major cardiovascular events in those with cardiovascular disease, such as death from cardiovascular disease, heart attack, stroke, angina requiring hospitalization, or certain types of heart surgery.

2025年2月1日 · It is also used to reduce the risk of death, heart attack, stroke, unstable angina (chest pain) requiring hospitalization, or certain types of heart surgery in patients with existing heart or blood vessel disease. This medicine is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor.

2017年5月4日 · Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%....

2024年5月21日 · Repatha (evolocumab) is commonly used for the following conditions. To lower the risk of heart attack, stroke, and certain types of heart surgery in people with heart disease

Adjunct to diet, alone or in combination with other lipid-lowering therapies (eg, statins), for treatment of primary hyperlipidemia, including heterozygous familial hyperlipidemia (HeFH), to reduce...